Barclays »

Aligos Therapeutics shares owned by Barclays

Quarter-by-quarter ownership of Aligos Therapeutics (ALGS) shares owned by Barclays from 13F filings

Historical chart of Barclays investment in Aligos Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aligos Therapeutics held by Barclays consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aligos Therapeutics by Barclays

Quarter filed Position value Share count Share price at filing
2025-09-30 $147 15 9.80

More positions owned by Barclays

Microsoft Corporation (MSFT)
SPDR S&ampP 500 ETF TR Fund (SPY)
Invesco Qqq Tr Fund (QQQ)
NVIDIA Corporation (NVDA)
Ishares Tr Fund (IWM)
Apple (AAPL)
Tesla Opt Put Option (TSLA)
Amazon Opt Call Option (AMZN)
Alphabet Opt Call Option (GOOGL)
Broadcom Opt Call Option (AVGO)
Facebook Inc cl a (META)
Ishares Tr Opt Call Option (HYG)
JPMorgan Chase & Co. (JPM)
Alphabet Opt Put Option (GOOG)
Berkshire Hathaway Inc Del Opt Put Option (BRK.B)

View all positions for Barclays

Top funds holding Aligos Therapeutics

Woodline Partners
Deep Track Capital
Alyeska Investment Group
Sio Capital Management
Readystate Asset Management
Vanguard Group
Adage Capital Partners GP
Baker Bros. Advisors
Hillhouse Capital Advisors
LPL Financial
Renaissance Technologies
Geode Capital Management
Two Sigma Investments
Squarepoint Ops
UBS Group

View all funds holding Aligos Therapeutics